<DOC>
	<DOC>NCT01281306</DOC>
	<brief_summary>The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).</brief_summary>
	<brief_title>An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Written informed consent must be obtained before any assessment is performed. Patients with mildtomoderate systolic hypertension, untreated or currently taking antihypertensive therapy. Ability to communicate and comply with all study requirements and demonstrate good medication compliance (â‰¥ 80% compliance rate) during the runin period. Severe hypertension History of angioedema, drugrelated or otherwise, as reported by the patient. Pregnant or nursing (lactating) women. Women of childbearing potential (WOCBP), UNLESS they are using adequate birth control methods. History or evidence of a secondary form of hypertension. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>LCZ696</keyword>
	<keyword>dual-acting</keyword>
	<keyword>neprilysin</keyword>
	<keyword>nep inhibitor</keyword>
	<keyword>vasopeptidase</keyword>
	<keyword>angiotensin receptor</keyword>
	<keyword>angiotensin receptor neprilysin inhibitor (ARNi)</keyword>
</DOC>